Poster: CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center

In our center, targeted therapies have become the most used treatment in CLL, with BTKi standing out followed by BCL2i, which reflects the historical development and approval of these agents. This study provides useful information for the design of therapeutic strategies for CLL both in the healthcare setting and in clinical trials in our country. No grant funding has been provided for this study.